Clinical Trials Directory

Trials / Completed

CompletedNCT06374017

Evaluation of Lidocaine Spray Versus Dexmetomidine Spray on Stress Response

Evaluating the Effect of Topical Lidocaine Spray Versus Dexmedetomidine Spray on Suppression of Stress Response to Laryngoscopy and Endotracheal Intubation: a Randomized Controlled Study

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
120 (actual)
Sponsor
Kasr El Aini Hospital · Academic / Other
Sex
All
Age
18 Years – 70 Years
Healthy volunteers
Not accepted

Summary

Many studies discussed attenuating stress response by various measures but to the interest of our study , No one compared topical spray of both lidocaine and dexmedetomidine in attenuating the haemodynamic stress responses of laryngoscopy and endotracheal intubation, avoiding undesired systemic effects of drugs ,

Detailed description

This study will be conducted in the operating theatres of Cairo university hospitals. Patients undergoing any surgery under general anesthesia and needs endotracheal intubation using direct laryngoscopy will be assigned to one of the three groups: Group C: will receive 5ml of normal saline sprayed via long nostril syringe into oropharynx, the vocal cords and tracheobronchial tree 5 minutes before intubation Group L: : will receive 5ml of lidocaine 2% (100mg) sprayed via long nostril syringe into oropharynx , the vocal cords and tracheobronchial tree 5 minutes before intubation Group D: : will receive dexmedetomidine (1 μg/kg) diluted in 5ml normal saline sprayed via long nostril syringe into oropharynx , the vocal cords and tracheobronchial tree 5 minutes before intubation.

Conditions

Interventions

TypeNameDescription
DRUGNormal saline, Lidocaine, dexmetomidineThe study drug of each group will be sprayed into oropharynx, the vocal cords and tracheal tree 3 minutes after induction of anesthesia and 5 minutes before intubation.

Timeline

Start date
2024-04-20
Primary completion
2024-12-30
Completion
2025-01-10
First posted
2024-04-18
Last updated
2025-04-02

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT06374017. Inclusion in this directory is not an endorsement.